Boston Scientific has secured CE Mark for its Vercise Primary Cell (PC) Deep Brain Stimulation (DBS) system for the treatment of Parkinson's disease (PD).
The Vercise PC system was designed to provide accurate neural targeting to address various requirements of patients suffering from PD, primary and secondary dystonia, and essential tremor.
Capable of finely controlling the size and shape of stimulation with multiple independent current control technology, the system also powers the Vercise DBS Directional Lead, the first commercially available eight-contact segmented lead with current steering.
The system comprises unique software solutions with a clinical effects map, which captures data over time and visually summarises the progress of individualised patient therapy, while allowing physicians to monitor and modify treatment as needed.
Boston Scientific neuromodulation president Maulik Nanavaty said: "This new system exemplifies the Boston Scientific commitment to advancing DBS therapy and providing impactful and transformative technology to reach a broader range of patients suffering from these debilitating diseases."
DBS therapy involves the placement of a device that stimulates specific areas in the brain using electrical signals.
The portfolio is said to be supported by a robust clinical programme, including the ongoing Intrepid clinical trial in the US and the Vantage study in Europe, with the latter demonstrating a significant and consistent improvement in motor scores as well as an increase in quality of life.
While the Vercise PC DBS system is not available for use or sale in the US, its rechargeable version is investigational in the country, and is currently being evaluated in the Intrepid study.
Image: The Vercise Deep Brain Stimulation system is designed for the treatment of Parkinson's disease. Photo: courtesy of Boston Scientific.